ArticlePloS one2025
Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality, with portal vein tumor thrombosis (PVTT) being a common complication that significantly worsens prognosis. Recent studies have identified bone mineral density (BMD) as a prognostic factor in patients with HCC; however, its role in patients with PVTT remains unexplored. This retrospective study evaluated the prognostic value of BMD in 462 patients with HCC and PVTT treated between 2005 and 2020. BMD was measured via computed tomography attenuation at the first lumbar vertebra at the time of HCC diagnosis and PVTT onset, using an established threshold of 160 Hounsfield units (HU). Kaplan-Meier analysis assessed overall survival, and multivariate Cox regression adjusted for established prognostic factors. Median BMD was 136 HU (IQR: 113-160) at HCC diagnosis and 134 HU (IQR: 109-159) at PVTT onset. Patients with BMD ≥ 160 HU showed significantly longer overall survival both at HCC diagnosis (10.4 vs. 5.5 months, p < 0.001) and PVTT onset (8.5 vs. 4.7 months, p < 0.001). In multivariate analysis at both time points, BMD remained an independent predictor of survival, alongside tumor growth pattern, therapy, and Albumin-Bilirubin (ALBI) grade (alpha-fetoprotein reached significance only at time of PVTT diagnosis). These findings suggest that BMD independently predicts survival in HCC with PVTT and may enhance prognostic modeling and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.